The Outcomes of Chronic Myeloid Leukemia Patients With Molecular Warning Responses During Imatinib Treatment According to the European LeukemiaNet 2013 Recommendations

Soysal T., Eskazan A. E., Serin I., Sadri S., Keskin D., Yurttas N. O., ...Daha Fazla

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, cilt.19, sa.7, 2019 (SCI-Expanded) identifier identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 19 Sayı: 7
  • Basım Tarihi: 2019
  • Doi Numarası: 10.1016/j.clml.2019.03.028
  • Dergi Adı: CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Anahtar Kelimeler: Chronic myeloid leukemia, European LeukemiaNet (ELN), Imatinib, Tyrosine kinase inhibitor, Warning, MANAGEMENT
  • Acıbadem Mehmet Ali Aydınlar Üniversitesi Adresli: Hayır

Özet

We retrospectively evaluated 73 chronic myeloid leukemia patients receiving first-line imatinib and compared patients with molecular warning response (WR) with patients with optimal response (OR) and failure regarding short- and long-term outcomes. The cumulative major molecular response (MMR) rates in patients with OR were significantly higher at any timepoint than those achieved by the WR group. Patients with WR at 3 months had significantly inferior failure-free survival (FFS) than optimal responders, but overall survival (OS) was similar. At 6 and 12 months, the WR and OR groups had similar FFS and OS. Twenty of 23 patients with WR at 12 months achieved MMR with imatinib.